Certara, Inc.

For Q2 2026, revenue was $93.3 million, up 1% year over year. Software revenue was $48.8 million, up 4%, and services revenue was $44.5 million, down 3%; total bookings were $98.3 million, up 1%, software bookings were $50.7 million, up 9%, and services bookings were $47.6 million, down 6%. Adjusted EBITDA was $26.2 million versus $27.0 million a year ago, with adjusted EBITDA margin of 28.1%; adjusted diluted EPS was $0.08, unchanged year over year. Net loss from continuing operations was $6.1 million versus net income of $1.5 million in Q2 2025, and diluted loss per share was $0.04 versus diluted EPS of $0.01. For the full year, management reaffirmed revenue growth of 0% to 4%, which translates to $367 million to $382 million on a comparable continuing-operations basis; software revenue is expected to be at or above the high end of the range, services at or below the low end. Full-year adjusted EBITDA margin is now expected to be 29% to 31%, and adjusted diluted EPS from continuing operations is expected to be $0.31 to $0.36.

Jon Resnick framed Q2 as an execution quarter and said Certara is being transformed into a company capable of delivering sustainable double-digit growth. He emphasized stronger foundational positioning, favorable macro trends in biopharma spending and clinical trial activity, and a major reset in go-to-market, product prioritization, and AI enablement. His tone was constructive but still cautious, repeatedly noting that the company is still in the early innings of the transformation and has more work to do.

Faiz Mohammed focused on the financial impact of the divestiture and the updated outlook. He noted the regulatory and medical writing business contributed $19.2 million of revenue and $7.5 million of adjusted EBITDA through the May 8 close, and said the business ended Q2 with $184.1 million of cash, $294 million of term loan borrowings, and $100 million of revolver availability. He also highlighted $17.4 million of Q2 share repurchases, the completion of the prior $100 million authorization, and a new $50 million repurchase program; on margins, he said the reduction in force should help offset stranded costs and support improvement in the second half.

Analysts focused on whether the revamped go-to-market model is working, what is driving the pipeline increase, the significance of the NVIDIA partnership, the impact of the divestiture on guidance and margins, and whether share buybacks or other capital deployment are planned. Resnick said renewals were slightly ahead of expectations, pipeline creation was up sharply, and services is being pushed back toward more specialist, science-led selling; he also said the NVIDIA deal is part of a broader next-generation platform strategy but declined to give timing for revenue impact. On capital allocation, he said there is no fixed execution plan, only the board’s new $50 million authorization and a continued disciplined stance. He also pushed back on concerns about regulation and biotech funding, saying adoption lags can exist but that Certara’s opportunity is more about execution and helping customers adopt emerging regulatory pathways.